Immunotherapy for skin cancer
The U.S. Food and Drug Administration has approved imiquimod (sold under several brand names) to treat superficial basal cell carcinomas. Imiquimod is an immunotherapy drug that works by activating the immune system to attack cancer cells. Specifically, imiquimod is designed to stimulate the body to produce interferon, a natural protein that fights foreign invaders as well as diseased or cancerous cells.
Imiquimod is prescribed as a topical cream that is applied directly to the tumor. It may be used alone or in combination with other skin cancer treatments.